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ABSTRACT
Steroid-dependentnephrotic syndrome (SDNS) carriesahigh riskof toxicity fromsteroidsor steroid-sparingagents.
Thisopen-label,noninferiority, randomizedcontrolledtrial at foursites in Italy testedwhether rituximab isnoninferior
to steroids in maintaining remission in juvenile SDNS. We enrolled children age 1–16 years who had developed
SDNS in the previous 6–12months andweremaintained in remissionwith high prednisone doses ($0.7mg/kg per
day). We randomly assigned participants to continue prednisone alone for 1 month (control) or to add a single
intravenous infusion of rituximab (375mg/m2; intervention). Prednisonewas tapered in both groups after 1month.
For noninferiority, rituximab had to permit steroid withdrawal and maintain 3-month proteinuria (mg/m2 per day)
withinaprespecifiednoninferioritymarginof three times the levels amongcontrols (primaryoutcome).We followed
participants for$1 year to compare risk of relapse (secondary outcome). Fifteen children per group (21 boys;mean
age, 7 years [range, 2.6–13.5 years]) wereenrolled and followed for#60months (median, 22months). Three-month
proteinuriawas42% lower in the rituximabgroup (geometricmean ratio, 0.58; 95%confidence interval, 0.18 to1.95
[i.e., within the noninferiority margin of three times the levels in controls]). All but one child in the control group
relapsedwithin 6months;median time to relapse in the rituximabgroupwas 18months (95%confidence interval, 9
to 32months). In the rituximab group, nausea and skin rash during infusion were common; transient acute arthritis
occurred in one child. In conclusion, rituximab was noninferior to steroids for the treatment of juvenile SDNS.
J Am Soc Nephrol 26: 2259–2266, 2015. doi: 10.1681/ASN.2014080799
Idiopathic nephrotic syndrome is characterized by
episodes of severe proteinuria and hypoalbuminemia
(serum albumin,2.5 g/dl) and is often associated
with dyslipidemia and hypercoagulability. It affects
2–10 children per 100,000 per year inWestern coun-
tries, with a prevalence of 16 cases per 100,000.1
Oral corticosteroids are the cornerstone of therapy
andinducediseaseremission inapproximately90%of
patients.2,3 However, up to 85% of these patients
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relapse within 5 years,4–8 and many will develop steroid depen-
dence. In this situation, the disease relapses within 2 weeks of
steroidwithdrawal and treatmentmust be continued indefinitely.
Clinical practice guidelines suggest using low-dose prednisone to
maintain remission in steroid-dependent forms of the disease
(evidence level 2C–D) and corticosteroid-sparing agents (i.e.,
calcineurin inhibitors) for children who develop steroid-related
adverse effects (evidence level 1B).1,9,10 Given the toxicity of these
agents, alternative treatment options must be investigated.11,12
Rituximab, a chimericmonoclonal anti-
CD20 antibody, is increasingly being used
as a steroid-sparing treatment option for
children with idiopathic nephrotic syn-
drome. However, this is based largely on
evidence from observational data, which
are known to overestimate treatment ben-
efits. One clinical trial in juvenile forms of
nephrotic syndrome treated with both
steroids and calcineurin inhibitors has
reported more modest benefits.13 A recent
trial reported more promising results in
similarly complicated forms of frequently
relapsing and steroid-dependent nephrotic
syndrome treated with both steroid and
immunosuppressant therapies.14 Overall,
all studies have demonstrated that rituxi-
mab has temporary effects, although op-
timal frequency of repeated infusions to
optimize benefits and minimize potential
risks is unknown. While long-term follow-
up data indicate that oral drug–free remis-
sion after rituximab injection tends to last
longer in children receiving combined
therapy who were initially dependent on
steroids alone and with shorter disease du-
ration,15 to date no trial has assessed the
use of rituximab in early-stage uncom-
plicated steroid-dependent nephrotic
syndrome (SDNS). We conducted a ran-
domized controlled trial in children with
SDNS who had normal levels of protein-
uria and whose state of complete remission
depended on high-dose steroids alone for
6–12 months (i.e., without calcineurin in-
hibitors) to determine whether rituximab
would be noninferior to steroids in main-
taining complete disease remission.
RESULTS
Study Participants
Between April 2009 and December 2012
we screened 80 children. Of these, all 30
eligible children consented to participate.
After the run-in period 15 were randomly assigned to each
study group (Figures 1 and 2) and followed until April 2014.
Reasons for ineligibility included steroid-resistant disease
(n=11), use of low-dose steroids (n=17), and treatment-free
remission (n=22). Although all participants were receiving
high-dose prednisone (.0.7 mg/kg per day) at the beginning
of the run-in period, at the end of the run-in period the average
prednisone doses were 0.1 mg/kg per day lower (see Concise
Methods). Participant characteristics at the end of the 1-month
Figure 1. Study design.
Figure 2. Flowchart. The parents of one participant in the treatment group withdrew
consent immediately after randomization. All remaining participants remained in the
study for at least 1 year. *Intention-to-treat principle.
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run-in period were similar in both study groups (Table 1). Mean
age of the participants was 7 years (range, 2.6–13.5 years), and
70% of patients were male. Average disease duration was 2.5
years. Before developing steroid-dependent disease, participants
had experienced amedian of 3 relapses (range, 2–8). Proteinuria
levels were in the normal range and were similar in both treat-
ment groups, as were average prednisone doses, levels of baseline
kidney function, serum albumin, and cholesterol. Three chil-
dren per group had received antiproliferative agents before the
study (five received cyclophosphamide and one received myco-
phenolate mofetil); all had been steroid dependent for 6–12
months at enrollment, and none had signs of steroid toxicity
(Supplemental Table 1) or growth deficit (Supplemental Table
2). All participants remained in the study for at least 1 year except
one, whose parents withdrew consent after randomization. Me-
dian duration of follow-upwas 22months (range, 1–60months).
Primary Outcome
Proteinuria increased at 3 months in the prednisone group
(37%; 95% confidence interval [95% CI], 7% to 76%) and
decreased in the rituximab group (237%; 95% CI, 220% to
-51%) (Table 2). After we accounted for baseline proteinuria,
3-month proteinuria was 42% lower in the treatment group
than the control group, although this did not reach statistical
significance (ratio of means, 0.58; 95% CI, 0.18 to 1.95). The
upper CI was below the prespecified noninferiority margin of
3 (Figure 3). Results of sensitivity analyses were the same (Sup-
plemental Table 3).
Secondary Outcomes
Figure 4 shows the proportion of children with proteinuria
.500 mg/m2 per day and those using prednisone or calci-
neurin inhibitors. Although levels of proteinuria remained
similar in the two groups, children treated with rituximab
were less likely to require steroids or steroid-sparing agents to
maintain remission. Themean6SDprednisone dose at 3months
was lower in the rituximab group than in the control group
(0.0960.21 versus 0.5460.39 mg/kg per day; P,0.001). Figure
5 summarizes 1-year relapse-free survival by treatment group.
Fourteen of 15 children in the control group relapsed during
tapering of the prednisone dose, whereas only 1 child in the
rituximab group relapsed within 6 months of randomization,
resulting in a significant difference between the two survival
curves (P,0.01). Of the participants assigned to the rituximab
group, relapse-free survival was 66% (95% CI, 38% to 85%) at 1
year and 34% (95% CI, 10% to 59%) at 2 years (Supplemental
Figure 1). By study end (follow-up range, 1–60 months), 14 re-
lapses had occurred in 9 children randomly assigned to rituximab
(relapse rate, 0.39 per patient-year; 95% CI, 0.26 to 0.61 per
patient-year), and 7 children had received one to three additional
rituximab courses. Six children in the rituximab group did not
experience a relapse. The median relapse-free time between rit-
uximab treatments was 18 months (95% CI, 9 to 32 months)
(Supplemental Figure 2).
Hematologic Data
CD20 countswere reduced to,1%at 1month in all participants
treated with rituximab. After 3 months, CD20 counts remained
undetectable in all these children. Mean time to CD20 reconsti-
tutionwas 5.8months (median, 5.5; range, 4–12months). None
of the participants had lymphocytopenia or neutropenia. Serum
levels of IgG 3months after rituximab infusionwere the same as
in the comparator group (Supplemental Table 4).
Adverse Events
During rituximab infusion, all participants reported mild
nausea and/or skin rash, which were successfully treated in all
cases by slowing the infusion rate and increasing the dose of
chlorfenamine. One participant had fever with migrating skin
rash and acute arthritis at the hip joint 32 days after the
rituximab infusion. Resolution was rapidly and completely
achieved in 48 hours with nonsteroidal anti-inflammatory
medications. No adverse events occurred in the control group.
DISCUSSION
This trialusedaparallel-arm,noninferioritydesigntotestwhether
rituximab was noninferior to standard care (prednisone) in
Table 1. Participant characteristics at randomization






Age (yr) 6.963.1 6.963.6
Boys (%) 11 (73) 10 (67)
Body weight (kg) 31614 30616
Disease duration (yr) 2.062.5 2.762.4
Median no. of relapses (range)a 2 (2–7) 3 (2–8)
Steroid toxicity (%)b 0 0
Prednisone dose (mg/kg per day) 0.6060.47 0.5760.42
ARB/ACEI use, n ( %) 2 (13%) 0
Urinary protein (mg/m2 per day) 76648 84639
Serum albumin (g/dl) 4.060.4 3.860.3
Serum cholesterol (mg/dl) 172620 164620
Serum creatinine (mg/dl) 0.4160.1 0.4060.2
Values are reported as means6SDs for quantitative variables (units) and as
absolute (n) and relative (%) frequencies for qualitative variables. ARB/ACEi,
angiotensin-receptor blockers or angiotensin-converting enzyme inhibitors.
aNumber of relapses before the development of steroid dependence.
bSee Supplemental Table 1 for definitions.





Mean Ratio Change (%)
Prednisone 49 (2 to 948) Reference Reference
Rituximab 28 (2 to 474) 0.58 (0.18 to 1.95) 242 (282 to 95)
Estimates and 95% CIs of the means of proteinuria at 3 months, their ratio,
and percentage change. The model is adjusted for baseline values of pro-
teinuria.
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maintaining proteinuria levels within the normal range. We
chose this design because the study population included children
successfully maintained in complete remission by prednisone
therapy. We found that a single infusion of rituximab allowed
steroid withdrawal in children with early-stage uncomplicated
SDNS andwas noninferior to steroids inmaintaining remission.
At 1 year, 66% of the children assigned to rituximab were still in
steroid-free remission. Median relapse-free time following each
infusionwas 18months, and the short-termadverse event profile
of rituximab included only reversible side effects during the drug
infusion. Steroid withdrawal was not possible in the control
group, and all children required a steroid-sparing agent within a
month of attempting the steroid taper.
Ourfindings in uncomplicated forms of SDND treatedwith
a single rituximab infusion complement those from a recent
Japanese trial. That trial reported a 73% reduction in the risk of
relapse (versus 98% in our study) and a median relapse-free
survival duration of 9months (versus 18months in our study)
in childrenwith complicated forms of frequently relapsing and
steroid-dependent nephrotic syndrome treated with four
weekly doses of rituximab.14 Important reasons might explain
this discrepancy. First, our study included only children with
uncomplicated disease responsive to and dependent on ste-
roids alone, as well as substantially shorter disease duration
at enrollment (2.5 versus 8 years). Second, our study was more
susceptible to bias because it was open label, whereas the Jap-
anese study was a double-blind, placebo-controlled trial.
Our study findings also echo those from two recent ob-
servational studies15,16 examining the role of rituximab as a
steroid-sparing agent in SDNS and involving
a total of 70 children and 20 adults. In both
studies, rituximab reduced the rate of relapse
and improved kidney function in children
with SDNS. The present randomized con-
trolled trial provides longer-term data con-
sistent with these findings.
The limited toxicityof rituximab and the
potential benefits of maintaining disease
remission while avoiding steroids and calci-
neurin inhibitorssupporttheuseofrituximab
as a steroid-sparing agent in juvenile SDNS,
but the effects of rituximab in other forms of
nephrotic syndrome remain uncertain. Data
from a previous trial, for example, do not
support the use of rituximab in childrenwith
nephrotic syndrome that is resistant to ste-
roids and calcineurin inhibitors.17 In forms
of nephrotic syndrome that depend on both
steroids and calcineurin inhibitors, rituximab
may be used to attain oral drug–free remis-
sion,13 but a single rituximab infusion may
be required as frequently as every 6months.15
While more doses may prolong drug-free re-
mission, this may increase the risk of adverse
events, such as neutropenia.18 In the Japanese
trial, for example, lymphocytopenia and neutropenia occurred in
17% and 8% of the children, respectively.14 Results from our
study suggest that oral drug–free remission may be up to three
times as long in children with a relatively recent diagnosis of
SDNS who are maintained in complete remission with steroids
alone.
The mechanisms mediating the effects of rituximab in
SDNS are not clear. Most participants in the present trial
remained in remission for several months after reconstitution
of CD20+ lymphocytes, suggesting that the clinical effect of
rituximab may continue beyond its biologic activity on CD20
Figure 3. Graphical representation of the analysis of covariance
model. The effect of rituximab is measured as ratio of geometric
means of proteinuria at 3 months (0.58; 95% CI, 0.18 to 1.95). The
upper limit of the CI (1.95) is smaller than the prespecified non-
inferiority margin of 3, corresponding to a 200% increment in pro-
teinuria compared with the control group. For results of this analysis
see Table 2.
Figure 4. Proportion of children with proteinuria.500 mg/m2 per day (top), receiving
prednisone (middle) or steroid-sparing agents (bottom) by treatment group. Light gray
indicates rituximab group; dark gray indicates control group.
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and that, therefore, CD20 levels alone are not helpful in de-
cision-making about timing of repeated infusions. Rituximab
depletes the B cell population, yet this disease has been his-
torically considered a T cell disorder19,20 that is potentially
mediated by a circulating factor.21,22 Published investigations
offer some insight as to potential explanations for this ap-
parent paradox.23–25 First, podocytes express the B cell costi-
mulatory molecule B7–1 in response to various pathologic
stimuli,26,27 and rituximab may delay the appearance of B7–1
on the podocytes, as in B cells of patients with non-Hodgkin
lymphoma.28 In support of this theory, abatacept, a blocker of
costimulatory molecules, has been used with success in five
cases of otherwise treatment-resistant FSGS.27 Second, deple-
tion of B cells may restore the regulatory T-cell popu-
lation,29,30 which is deficient in nephrotic syndrome.19,31
Rituximab may also deplete the IL-17–producing CD4+
T cells (Th17), which express CD20 on their surface and
have been implicated in the pathogenesis of the disease.32,33
The anti-Th17 effect of rituximab formed the theoretical basis
for its use in rheumatoid arthritis34–37 and in small vessel
vasculitis.38 Finally, rituximab exerts direct and nonimmuno-
logic effects on the podocyte. Rituximab binds to the sphingo-
myelin phosphodiesterase acid–like 3b protein (SMPDL3b)
expressed in the podocyte lipid raft microdomains, the critical
plasma membrane signaling platforms for the regulation of
the cell cytoskeleton.39 Binding of rituximab to SMPDL3b
may prevent the downregulation of the acid sphingomyelinase
activity induced by FSGS sera and preserve podocyte structure
and function.39
Our study has limitations, including fail-
ure to use placebo among controls, lack of
blinding, and small sample size.However,we
worked tomitigate the consequences of these
sources of bias by treating all participants
with the same steroid-tapering schedule,
using an objective laboratory measure as
the outcome, minimizing type I and type II
errors in our sample size calculation, and
following patients for up to 5 years.
Several questions need to be addressed
before rituximab use on a large scale can be
recommended.Dataarenotavailableonlong-
term benefits and harms or on the optimal
frequency of repeated rituximab infusions,
particularly in children relapsing within
6 months of the first rituximab infusion (1
of 15 children in this study).Wedonotknow
whether SDNS is a progressive disease or
a disease that affects some children more
severely thanothers, and thereforewedonot
know whether the strategy to maximize the
benefits of rituximab therapy should be
based on the stage of the disease or the
patient characteristics. Preliminary data
from this study indicate that most children
can be maintained in remission using rituximab treatment
alone with repeated infusions every 9–30 months. Second, the
long-term safety of rituximab remains uncertain, including the
risk of malignancy and progressive multifocal leukoencephal-
opathy. According to a recent systematic review, these longer-
term adverse events that have been reported in the literature
occurred in individuals who had received other immuno-
suppressive medications before rituximab and in nonrenal
patients.40 Finally, most recent reports, including the present
trial, have included only white patients, and further studies of
patients from different ethnic groups are needed.
In summary, data from thepresent clinical trial indicate that
rituximab allows the completewithdrawal of steroids in juvenile,
steroid-dependent forms of nephrotic syndrome without ad-
versely affecting clinical outcomes and has an acceptable short-
term adverse event profile.
CONCISE METHODS
Trial Design
This multicenter, open-label, randomized, noninferiority trial was
conducted at four sites in Italy between April 2009 and April 2014,
with a plannedminimum follow-up of 1 year. Participants underwent a
1-monthrun-inperiodduringwhich instructiononurinecollectionand
dipstick readings were carefully reviewed, proteinuria was monitored,
adherence assessed, and oral prednisone dose reduced to the minimum
dose required in the previous 6 months. Following randomization,
steroidtreatmentwascontinuedfor1monthandthentaperedastolerated
Figure 5. One-year relapse-free survival by treatment group in the prednisone
(control; dark gray) and rituximab (intervention; light gray) groups. The risk of relapse
was reduced by 98% in children treated with rituximab (hazard ratio, 0.02; 95% CI, 0.01
to 0.15). C, comparator group; I, intervention group; R, randomization.
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inbothgroups.Steroidswere taperedinanattempttodeterminewhether
a single pulse of rituximab would allow complete steroid withdrawal
and maintain steroid-free remission. A parallel-arm, noninferiority
designwasused to testwhether rituximabwasnoninferior to standard
care (prednisone) in maintaining proteinuria levels within a pre-
specified margin. An independent data and safety monitoring board
reviewed safety data once half the participants had been enrolled and
again at the end of the study. The protocol was approved by the ethics
committee of the coordinating and data collection center and
registered in the European Clinical Trials Database (EudraCT:
2008–004486–26).
Participants
Eligible participants were 1–16 years of age with an eGFR.60ml/min
per 1.73 m241,42 who had idiopathic, steroid-dependent nephrotic
syndrome for a minimum of 6 to a maximum of 12 months at the
time of study entry, regardless of disease duration. Participants must
have been receiving high-dose steroids ($0.7 mg/kg per day)1 con-
tinuously to maintain remission for the 3 months preceding enroll-
ment. Participants were excluded if they had received calcineurin
inhibitors at any time or had received cyclophosphamide or myco-
phenolate in the 6 months before enrollment.
Nephrotic syndrome was defined as proteinuria in the nephrotic
range (.1000 mg/m2 per day or protein-to-creatinine ratio.4 mg/mg
in a single urine specimen) or proteinuria ranging from 250 to 1000
mg/m2 per day in associationwith hypoalbuminemia (serum albumin
,2.5 g/dl) or dyslipidemia (total cholesterol.250 mg/dl). Remission
was defined as stable proteinuria,150 mg/m2 per day. Genetic testing
and renal biopsy were not required because juvenile nephrotic syn-
drome is diagnosed largely on the basis of a response to prednisone, as
per Kidney Disease Improving Global Outcomes guidelines.1 Cases
were considered steroid dependent if patients responded to full doses
of prednisone (2 mg/kg) but experienced two consecutive relapses
during prednisone tapering or within 2 weeks of prednisone with-
drawal.1 Angiotensin-converting enzyme inhibitors or angiotensin-
receptor blockers were used at the discretion of the investigators and
were kept constant during the study.
We excluded children with previous episodes of macrohematuria,
a history of hepatitis B or C,HIV infection, positivity of anymarker of
autoimmunity (antinuclear antibody, nuclear DNA, ANCA), and low
complement C3 levels. Children requiring diuretics, albumin, or
anticoagulants were also excluded.
Randomization and Masking
Participantswere randomly assigned in a 1:1 ratio to continue standard
therapy alone (oral prednisone) or standard therapy plus a single
infusionof rituximab.Randomizationwasdone followingapermuted-
block design with blocks of variable sizes (4–6). A distant site with no
clinical involvement in the trial generated the randomization list and
kept the allocation concealed. Assignments were notified electroni-
cally after signed consent was obtained (and assent for participants
who were capable of assenting). Because of the nature of the interven-
tion, clinical investigators and study nurses were not blinded to group
assignment, nor were participants.
Study Treatments
In the interventiongroup, rituximab(MabThera/RITUXAN;375mg/m2)
was diluted in normal saline (1 mg/ml) and administered at a rate of
0.5–1.5 ml/min over approximately 6 hours following the infusion of
2.5–5 mg of intravenous chlorfenamine maleate (based on the local
protocol and patient tolerance), methylprednisolone (2 mg/kg) in
normal saline, and oral paracetamol (8 mg/kg). In both groups, pred-
nisone was continued at the same doses as during the run-in, then
tapered off by 0.3 mg/kg per week starting at 30 days and withdrawn if
proteinuria levels were still,1 g/m2 per day at the end of the taper. In
both groups treatment was restarted if proteinuria was $1 g/m2 per
day during follow-up. In the control group, relapses were treated with
prednisone (maximum dose, 2 mg/kg per day) or steroid-sparing
agents, including cyclosporine, tacrolimus, or cyclophosphamide, at
the discretion of local investigators. Rituximab could be used only
after failure of other steroid-sparing agents. In the treatment group
relapses were treated with rituximab.
Follow-up
Study visits occurred at baseline and every 3months thereafter, unless
complications or relapses occurred. Study coordinators maintained
ongoing contactwith the children, their families, and the family physician
to collect clinical data, including BP and potential adverse events
(Supplemental Table 5). Proteinuria was evaluated daily using a simple
dipstick test andmonthly using a 24-hoururine collection. Because of the
frequent false-positivity of dipsticks,43 we planned a 24-hour urine col-
lection for readings of$1+. Kidney function, plasma proteins, and cho-
lesterol values weremeasuredmonthly.White blood cell and lymphocyte
population counts were monitored monthly in the rituximab group.
Outcomes
Participants randomly assigned to rituximab therapy were compared
with those receiving standard care for the primary outcome of the per-
centage change in daily proteinuria at 3 months. The primary outcome
was assessed at 3 months because most SDNS relapses occur within 2
weeks of prednisone withdrawal. We assessed the risk of relapse during
the year following randomization as a secondary endpoint and collected
data on repeated relapses beyond the initial year. Relapsewas defined as
proteinuria of 1000mg/m2 per day (protein-to-creatinine ratio.4mg/mg)
or proteinuria.500 mg/m2 per day (protein-to-creatinine ratio,
2–4 mg/mg) that was associated with hypoalbuminemia.
Statistical Analyses
This study was designed to evaluate whether rituximab was noninferior
to standard care in maintaining proteinuria levels in remission with a
noninferioritymarginof3 for thegeometricmeanratio.Thismarginwas
based on previous studies, which reported average proteinuria in
children in remission as,300 mg/m2 per day1; a level three times this
value remains below the 1000 mg/m2 per day threshold at which pred-
nisone treatment is usually started to treat relapses. We assumed a log-
normal distribution of proteinuria and used information from a prior
study on its SD.13 With a coefficient of variation of 0.85 (coefficient of
variation=exp[SD2]21) and a type I error rate of 0.01, we estimated
that 30 participants would provide a power of 90% to detect a ratio of
the geometric means of proteinuria between treatment and control
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groups,3 (i.e., lower than the prespecified margin), after accounting
for a 5% risk of withdrawals.44We analyzed outcome data according to
the intention-to-treat principle, with no interim or subgroup analyses.
Wemodeled 3-month log-transformed proteinuria using an analysis of
covariance model with treatment as factor and log-transformed base-
line proteinuria as covariate (primary analysis). Missing values at 3
months were replaced using the last-observation-carried-forward
method. We conducted sensitivity analyses replacing missing data at
3 months alternately with the highest and the lowest proteinuria value
in the study group and using a per-protocol approach. We used the
Kaplan-Meier method to describe 1-year relapse-free survival and Cox
regression to estimate the effect of treatment. We censored participants
at the study end date if they were event free or at the time they left the
study (main analyses). In sensitivity analyses we assumed that the event
occurred at the last observation time for participants who left the study
before the planned 1-year follow-up. We used two-sided tests with a
significance level of 0.05 for all analyses.We used Stata software, version
13.1 (http://www.stata.com), and R software, version 3.0.2 (http://
www.R-project.org) for all analyses.
ACKNOWLEDGMENTS
The authors thank Ms. Adriane Lewin for reviewing the reporting
material before submission and the research assistants, nurses, and
patients and families at all participating centers (Genoa,Milan, Foggia,
and Padua) who made this study possible.
The present study was investigator initiated and driven. The In-
stitute Giannina Gaslini provided financial and logistic support to the
trial and was in turn supported by funds deriving from Cinque per
mille of IRPEF-Finanziamento della ricerca sanitaria, the Italian
Ministry of Health, The Renal Child Foundation, and the Fondazione
La Nuova Speranza (Progetto integrato per la definizione dei mec-
canismi implicati nella glomerulo sclerosi focale).
The data safety and monitoring board members included Antonella
Trivelli,GiovanniCandiano,GiorgioPiaggio,andGianlucaCaridi.G.M.G.
and P.M. declare that all persons who contributed significantly to the
work have been here acknowledged. They confirm that they had full
access to all the study data and hadfinal responsibility for the decision to
submit the study results for publication. In addition, they affirm that this
manuscript is an honest, accurate, and transparent account of the study,
that no important aspects of the study have been omitted, and that any
discrepancies from the study as registered have been explained.
DISCLOSURES
All authors have completed the Unified Competing Interest form at www.
icmje.org/coi_disclosure.pdf (available on request from the corresponding
author). J.R. has received fees from Genetech and Roche.
REFERENCES
1. Radhakrishnan J, Cattran DC: The KDIGO practice guideline on glo-
merulonephritis: reading between the (guide)lines—application to the
individual patient. Kidney Int 82: 840–856, 2012
2. Korbet SM, Schwartz MM, Lewis EJ: Primary focal segmental glomer-
ulosclerosis: Clinical course and response to therapy. Am J Kidney Dis
23: 773–783, 1994
3. McEnery PT, Strife CF:Nephrotic syndrome in childhood.Management
and treatment in patients with minimal change disease, mesangial
proliferation, or focal glomerulosclerosis. Pediatr Clin North Am 29:
875–894, 1982
4. Ghiggeri GM, CarraroM, Vincenti F: Recurrent focal glomerulosclerosis
in the era of genetics of podocyte proteins: Theory and therapy.
Nephrol Dial Transplant 19: 1036–1040, 2004
5. ISKDC: Primary nephrotic syndrome in children: Clinical significance of
histopathologic variants of minimal change and of diffuse mesangial
hypercellularity. A report of the International Study of KidneyDisease in
Children. Kidney Int 20: 765–771, 1981
6. Kyrieleis HA, Löwik MM, Pronk I, Cruysberg HR, Kremer JA, Oyen WJ,
van den Heuvel BL, Wetzels JF, Levtchenko EN: Long-term outcome of
biopsy-proven, frequently relapsing minimal-change nephrotic syn-
drome in children. Clin J Am Soc Nephrol 4: 1593–1600, 2009
7. Ponticelli C, Zucchelli P, Imbasciati E, Cagnoli L, Pozzi C, Passerini P,
Grassi C, Limido D, Pasquali S, Volpini T, Sasdelli M, Locatelli F: Con-
trolled trial of methylprednisolone and chlorambucil in idiopathic
membranous nephropathy. N Engl J Med 310: 946–950, 1984
8. Trompeter RS, Lloyd BW, Hicks J, White RH, Cameron JS: Long-term
outcome for children withminimal-change nephrotic syndrome. Lancet
1: 368–370, 1985
9. Hodson EM, Knight JF, Willis NS, Craig JC: Corticosteroid therapy for
nephrotic syndrome in children. Cochrane Database Syst Rev (1):
CD001533, 2005
10. ISKDC: Nephrotic syndrome in children: Prediction of histopathology
from clinical and laboratory characteristics at time of diagnosis. A report
of the International Study of Kidney Disease in Children. Kidney Int 13:
159–165, 1978
11. Filler G: Treatment of nephrotic syndrome in children and controlled
trials. Nephrol Dial Transplant 18 Suppl 6: vi75–78, 2003
12. Ghiggeri GM, Catarsi P, Scolari F, Caridi G, Bertelli R, Carrea A, Sanna-
Cherchi S, Emma F, Allegri L, Cancarini G, Rizzoni GF, Perfumo F:
Cyclosporine in patients with steroid-resistant nephrotic syndrome: An
open-label, nonrandomized, retrospective study. Clin Ther 26: 1411–
1418, 2004
13. Ravani P, Magnasco A, Edefonti A, Murer L, Rossi R, Ghio L, Benetti E,
Scozzola F, Pasini A, Dallera N, Sica F, Belingheri M, Scolari F, Ghiggeri
GM: Short-term effects of rituximab in children with steroid- and cal-
cineurin-dependent nephrotic syndrome: A randomized controlled
trial. Clin J Am Soc Nephrol 6: 1308–1315, 2011
14. Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, Miura K, Aya K,
Nakanishi K, Ohtomo Y, Takahashi S, Tanaka R, Kaito H, Nakamura H,
Ishikura K, Ito S, Ohashi Y; Rituximab for Childhood-onset Refractory
Nephrotic Syndrome (RCRNS) Study Group: Rituximab for childhood-
onset, complicated, frequently relapsing nephrotic syndrome or ste-
roid-dependent nephrotic syndrome: A multicentre, double-blind,
randomised, placebo-controlled trial. Lancet 384: 1273–1281, 2014
15. Ravani P, Ponticelli A, Siciliano C, Fornoni A, Magnasco A, Sica F,
Bodria M, Caridi G, Wei C, Belingheri M, Ghio L, Merscher-Gomez S,
Edefonti A, Pasini A, Montini G, Murtas C,Wang X,Muruve D, Vaglio A,
Martorana D, Pani A, Scolari F, Reiser J, Ghiggeri GM: Rituximab is
a safe and effective long-term treatment for children with steroid
and calcineurin inhibitor-dependent idiopathic nephrotic syndrome.
Kidney Int 84: 1025–1033, 2013
16. Ruggenenti P, Ruggiero B, Cravedi P, Vivarelli M,Massella L,MarasàM,
Chianca A, RubisN, Ene-IordacheB, RudnickiM, Pollastro RM, Capasso
G, Pisani A, Pennesi M, Emma F, Remuzzi G; Rituximab in Nephrotic
Syndrome of Steroid-Dependent or Frequently Relapsing Minimal
Change Disease Or Focal Segmental Glomerulosclerosis (NEMO)
Study Group: Rituximab in steroid-dependent or frequently relapsing
idiopathic nephrotic syndrome. J Am Soc Nephrol 25: 850–863, 2014
J Am Soc Nephrol 26: 2259–2266, 2015 Rituximab for Idiopathic Nephrotic Syndrome 2265
www.jasn.org CLINICAL RESEARCH
17. Magnasco A, Ravani P, Edefonti A, Murer L, Ghio L, Belingheri M,
Benetti E, Murtas C, Messina G, Massella L, Porcellini MG, Montagna
M, Regazzi M, Scolari F, Ghiggeri GM: Rituximab in children with
resistant idiopathic nephrotic syndrome. J Am Soc Nephrol 23:
1117–1124, 2012
18. Kamei K, Takahashi M, Fuyama M, Saida K, Machida H, Sato M, Ogura
M, Ito S: Rituximab-associated agranulocytosis in children with re-
fractory idiopathic nephrotic syndrome: case series and review of lit-
erature [published online ahead of print August 1, 2014]. Nephrol Dial
Transplant 10.1093/ndt/gfu258
19. Le Berre L, Bruneau S, Naulet J, Renaudin K, Buzelin F, Usal C, Smit H,
Condamine T, Soulillou JP, Dantal J: Induction of T regulatory cells at-
tenuates idiopathic nephrotic syndrome. J Am Soc Nephrol 20: 57–67,
2009
20. Shalhoub RJ: Pathogenesis of lipoid nephrosis: A disorder of T-cell
function. Lancet 2: 556–560, 1974
21. McCarthy ET, Sharma M, Savin VJ: Circulating permeability factors in
idiopathic nephrotic syndrome and focal segmental glomerulo-
sclerosis. Clin J Am Soc Nephrol 5: 2115–2121, 2010
22. Wei C, TrachtmanH, Li J, DongC, FriedmanAL,Gassman JJ,McMahan
JL, Radeva M, Heil KM, Trautmann A, Anarat A, Emre S, Ghiggeri GM,
Ozaltin F, Haffner D, Gipson DS, Kaskel F, Fischer DC, Schaefer F,
Reiser J; PodoNet and FSGS CT Study Consortia: Circulating suPAR in
two cohorts of primary FSGS. J Am Soc Nephrol 23: 2051–2059, 2012
23. Fervenza FC, Abraham RS, Erickson SB, Irazabal MV, Eirin A, Specks U,
Nachman PH, Bergstralh EJ, Leung N, Cosio FG, Hogan MC, Dillon JJ,
Hickson LJ, Li X, Cattran DC; Mayo Nephrology Collaborative Group:
Rituximab therapy in idiopathic membranous nephropathy: A 2-year
study. Clin J Am Soc Nephrol 5: 2188–2198, 2010
24. Stasi R, CooperN, Del PoetaG, Stipa E, Laura EvangelistaM,Abruzzese
E, Amadori S: Analysis of regulatory T-cell changes in patients with
idiopathic thrombocytopenic purpura receiving B cell-depleting ther-
apy with rituximab. Blood 112: 1147–1150, 2008
25. Vallerskog T, Gunnarsson I, Widhe M, Risselada A, Klareskog L, van
Vollenhoven R, Malmström V, Trollmo C: Treatment with rituximab af-
fects both the cellular and the humoral arm of the immune system in
patients with SLE. Clin Immunol 122: 62–74, 2007
26. Reiser J, von Gersdorff G, Loos M, Oh J, Asanuma K, Giardino L,
Rastaldi MP, Calvaresi N, Watanabe H, Schwarz K, Faul C, Kretzler M,
DavidsonA, SugimotoH, Kalluri R, SharpeAH, Kreidberg JA,Mundel P:
Induction of B7-1 in podocytes is associated with nephrotic syndrome.
J Clin Invest 113: 1390–1397, 2004
27. Yu CC, Fornoni A, Weins A, Hakroush S, Maiguel D, Sageshima J, Chen
L, CiancioG, FaridiMH,BehrD, Campbell KN,Chang JM,ChenHC,Oh
J, Faul C, Arnaout MA, Fiorina P, Gupta V, Greka A, Burke GW 3rd,
Mundel P: Abatacept in B7-1-positive proteinuric kidney disease.
N Engl J Med 369: 2416–2423, 2013
28. NishioM, Fujimoto K, Yamamoto S, Endo T, Sakai T, ObaraM, Kumano
K, Yamaguchi K, Takeda Y, Goto H, Sato N, Koizumi K, Mukai M, Koike
T: Delayed redistribution of CD27, CD40 and CD80 positive B cells and
the impaired in vitro immunoglobulin production in patients with non-
Hodgkin lymphoma after rituximab treatment as an adjuvant to autol-
ogous stem cell transplantation. Br J Haematol 137: 349–354, 2007
29. Saadoun D, Rosenzwajg M, Landau D, Piette JC, Klatzmann D, Cacoub
P: Restoration of peripheral immune homeostasis after rituximab in
mixed cryoglobulinemia vasculitis. Blood 111: 5334–5341, 2008
30. Sfikakis PP, Souliotis VL, Fragiadaki KG, Moutsopoulos HM, Boletis JN,
Theofilopoulos AN: Increased expression of the FoxP3 functional
marker of regulatory T cells following B cell depletion with rituximab in
patients with lupus nephritis. Clin Immunol 123: 66–73, 2007
31. Bertelli R, Trivelli A, Magnasco A, Cioni M, Bodria M, Carrea A,
Montobbio G, Barbano G, Ghiggeri GM: Failure of regulation results in
an amplified oxidation burst by neutrophils in children with primary
nephrotic syndrome. Clin Exp Immunol 161: 151–158, 2010
32. Couser WG: Basic and translational concepts of immune-mediated
glomerular diseases. J Am Soc Nephrol 23: 381–399, 2012
33. Liu LL, Qin Y, Cai JF, Wang HY, Tao JL, Li H, Chen LM, Li MX, Li XM, Li
XW: Th17/Treg imbalance in adult patients with minimal change ne-
phrotic syndrome. Clin Immunol 139: 314–320, 2011
34. Pierson ER, Stromnes IM, Goverman JM: B cells promote induction of
experimental autoimmune encephalomyelitis by facilitating reactivation
of T cells in the central nervous system. J Immunol 192: 929–939, 2014
35. Vaglio A, Buzio C, Zwerina J: Eosinophilic granulomatosis with poly-
angiitis (Churg-Strauss): State of the art. Allergy 68: 261–273, 2013
36. van de Veerdonk FL, Lauwerys B, Marijnissen RJ, Timmermans K, Di
Padova F, Koenders MI, Gutierrez-Roelens I, Durez P, Netea MG, van der
Meer JW, van den Berg WB, Joosten LA: The anti-CD20 antibody ritux-
imab reduces theTh17cell response.Arthritis Rheum63:1507–1516, 2011
37. Yamamoto A, Sato K, Miyoshi F, Shindo Y, Yoshida Y, Yokota K,
Nakajima K, Akiba H, Asanuma Y, Akiyama Y, Mimura T: Analysis of
cytokine production patterns of peripheral blood mononuclear cells
from a rheumatoid arthritis patient successfully treated with rituximab.
Modern Rheumatol 20: 183–187, 2010
38. Kallenberg CG: Pathophysiology of ANCA-associated small vessel
vasculitis. Curr Rheumatol Rep 12: 399–405, 2010
39. Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R,
Jauregui AN, Li J, Mattiazzi A, Ciancio G, Chen L, Zilleruelo G, Abitbol
C, Chandar J, Seeherunvong W, Ricordi C, Ikehata M, Rastaldi MP,
Reiser J, Burke GW 3rd: Rituximab targets podocytes in recurrent focal
segmental glomerulosclerosis. Sci Transl Med 3: 85ra46, 2011
40. Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, Pollono EN, Cueto JP,
Gonzales-Crespo MR, Fulton S, Suarez-Almazor ME: Risk of malignan-
cies in patients with rheumatoid arthritis treated with biologic therapy:
A meta-analysis. JAMA 308: 898–908, 2012
41. Schwartz GJ, Gauthier B: A simple estimate of glomerular filtration rate
in adolescent boys. J Pediatr 106: 522–526, 1985
42. Schwartz GJ, Muñoz A, Schneider MF, Mak RH, Kaskel F, Warady BA,
Furth SL: New equations to estimate GFR in children with CKD. J Am
Soc Nephrol 20: 629–637, 2009
43. Hogg RJ, Portman RJ, Milliner D, Lemley KV, Eddy A, Ingelfinger J:
Evaluation and management of proteinuria and nephrotic syndrome in
children: Recommendations from a pediatric nephrology panel estab-
lished at the National Kidney Foundation conference on proteinuria,
albuminuria, risk, assessment, detection, and elimination (PARADE).
Pediatrics 105: 1242–1249, 2000
44. Wolfe R, Carlin JB: Sample-size calculation for a log-transformed out-
come measure. Control Clin Trials 20: 547–554, 1999
This article contains supplemental material online at http://jasn.asnjournals.
org/lookup/suppl/doi:10.1681/ASN.2014080799/-/DCSupplemental.
2266 Journal of the American Society of Nephrology J Am Soc Nephrol 26: 2259–2266, 2015
CLINICAL RESEARCH www.jasn.org
